Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The molecular pathology of cancer.

Harris TJ, McCormick F.

Nat Rev Clin Oncol. 2010 May;7(5):251-65. doi: 10.1038/nrclinonc.2010.41. Epub 2010 Mar 30. Review.

PMID:
20351699
2.

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.

Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, Imaizumi K, Kume H, Hasegawa Y, Shimokata K, Sekido Y.

Lung Cancer. 2005 Dec;50(3):385-91. Epub 2005 Sep 2.

PMID:
16140420
3.

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S, Cognetti F, Buttitta F.

Neoplasia. 2009 Oct;11(10):1084-92.

4.

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG.

J Thorac Oncol. 2012 Dec;7(12):1815-22. doi: 10.1097/JTO.0b013e31826bb7b2.

6.

EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.

Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Matsumura A, Okumura M, Tanaka H, Kawaguchi T, Shimizu T, Takeuchi H, Yano M, Fukai I, Fujii Y.

Clin Cancer Res. 2005 Apr 15;11(8):2924-9.

7.

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.

Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M.

Clin Cancer Res. 2009 Jul 15;15(14):4554-60. doi: 10.1158/1078-0432.CCR-09-0089. Epub 2009 Jul 7.

8.

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W.

J Thorac Oncol. 2008 Feb;3(2):111-6. doi: 10.1097/JTO.0b013e318160c607.

9.

SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.

Zhang L, Li QX, Wu HL, Lu X, Yang M, Yu SY, Yuan XL.

Ann Oncol. 2014 Aug;25(8):1584-90. doi: 10.1093/annonc/mdu172. Epub 2014 Jun 13.

PMID:
24928833
10.

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L.

Breast Cancer Res Treat. 2012 Jul;134(1):333-43. doi: 10.1007/s10549-012-2035-3. Epub 2012 Apr 27.

11.

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF.

Clin Cancer Res. 2004 Dec 15;10(24):8195-203.

12.

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.

Borràs E, Jurado I, Hernan I, Gamundi MJ, Dias M, Martí I, Mañé B, Arcusa A, Agúndez JA, Blanca M, Carballo M.

BMC Cancer. 2011 Sep 24;11:406. doi: 10.1186/1471-2407-11-406.

13.

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.

Chang JW, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, Tsai HY, Chen YH, Chen YT, Hsu HY, Chen YT, Tsai SF, Chen YR, Hsi BL, Huang SF.

Lung Cancer. 2008 Sep;61(3):328-39. doi: 10.1016/j.lungcan.2008.01.009. Epub 2008 Mar 4.

PMID:
18304690
14.

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.

Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.

Int J Cancer. 2014 Jun 1;134(11):2560-71. doi: 10.1002/ijc.28594. Epub 2013 Dec 13.

15.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
16.

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY.

Cancer Genet Cytogenet. 2007 Mar;173(2):107-13.

PMID:
17321325
17.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

18.

[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].

Liu B, Shi SS, Wang X, Xu Y, Zhang XH, Yu B, Lu ZF, Wang JD, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001. Chinese.

PMID:
23157740
19.

[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].

Sun LN, Luan HL, Zang FL, Wang M, Dong N, Guo Y, Sun BC, Zhan ZL.

Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):667-70. Chinese.

PMID:
21122380
20.

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.

Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan VE, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M.

Oncogene. 2009 Aug 6;28(31):2773-83. doi: 10.1038/onc.2009.135. Epub 2009 Jun 15.

Supplemental Content

Support Center